In this free webinar, see how a digital endpoint strategy can improve endpoint sensitivity and data quality in multiple sclerosis (MS) trials. Attendees will recognize how traditional MS endpoints can fail to detect meaningful change, and how innovative digital solutions could help detect disease progression and treatment effects earlier. The featured speakers will share how AI-enabled quantitative imaging delivers more consistent and objective measurements, reducing variability in imaging-based endpoints. Attendees will understand how to design and optimize eCOA endpoint strategies in MS trials, ensuring that accurate data is collected reliably from patients and clinical raters. The speakers will also discuss how instrumented gait and balance assessments add objective insight into motor function, complementing clinical and patient-reported measures.

TORONTO, March 3, 2026 /PRNewswire/ — How advances in brain imaging, eCOA solutions and instrumented movement analysis are redefining endpoint strategy in multiple sclerosis drug development

Traditional endpoints in multiple sclerosis trials often lack sensitivity to subtle disease progression and treatment effects. Novel digital endpoints are addressing these limitations by enabling more objective, quantitative assessment of neurological change.

In this webinar, the featured speaker will explore the use of AI-enabled quantitative medical imaging, optimized eCOA solutions and deployment strategies and precision instrumented motion analysis to improve endpoint sensitivity, data quality and decision-making in multiple sclerosis drug development.

Register for this webinar to learn how a digital endpoint strategy can improve endpoint sensitivity and data quality in multiple sclerosis trials.

Join experts from Clario, Todd Rudo (Moderator), MD, EVP, Chief Medical Officer; Laura Khurana, MPH, Senior Principal Scientific Advisor, eCOA Science & Consulting; Douglas Arnold, MD, Professor, Department of Neurology & Neurosurgery, McGill University; President and CEO, NeuroRx; Senior Advisor; and Vrutangkumar V. PhD, Director of Data Science and Biostatistics, Precision Motion, for the live webinar on Tuesday, March 24, 2026, at 11am EDT (4pm CET/EU-Central).

For more information, or to register for this event, visit A Modern Approach to Multiple Sclerosis Trials Applying Innovative Digital Endpoint Solutions.

Xtalks — The Life Science Community™ empowers professionals across pharma, biotech, medtech, healthcare and research with the trusted knowledge and collaborative insights that move the industry forward. Powered by Honeycomb Worldwide Inc., Xtalks delivers news, feature articles, webinars, podcasts, videos, expert interviews, curated job opportunities and more designed to support informed decision-making in a fast-evolving sector.

Every year, thousands of professionals rely on Xtalks for timely intelligence, peer perspectives and industry thought leadership. Join our life science community to stay informed, connected and ready for what’s next.

To learn more about Xtalks, visit www.xtalks.com

For information about working with Xtalks to host your webinar, visit https://xtalks.com/partner-with-us/

Contact:
Vera Kovacevic
Tel: +1 (416) 977-6555 x371
Email: [email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/a-modern-approach-to-multiple-sclerosis-trials-applying-innovative-digital-endpoint-solutions-upcoming-webinar-hosted-by-xtalks-302701931.html